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Systemic corticosteroid therapy is recommended as a ﬁrst-line treatment for acute graft-versus-host disease
(GVHD). We performed a retrospective study to identify the factors affecting the response of grade II to IV
acute GVHD to systemic corticosteroid therapy using the Japanese national registry data for patients who
received ﬁrst allogeneic hematopoietic cell transplantation with bone marrow (BM) (n ¼ 1955), peripheral
blood stem cells (PBSCs) (n ¼ 642), or umbilical cord blood (UCB) (n ¼ 839). Of 3436 patients, 2190 (63.7%)
showed improvement of acute GVHD to ﬁrst-line therapy with corticosteroids. Various factors were identiﬁed
to predict corticosteroid response. Interestingly, UCB (versus HLA-matched related BM) transplantation was
signiﬁcantly associated with a higher probability of improvement, whereas HLA-matched unrelated BM and
HLA-mismatched stem cell sources other than UCB were signiﬁcantly associated with a lower probability of
improvement. HLA-matched related PBSC transplantation was not signiﬁcantly different from HLA-matched
related BM transplantation. Patients without improvement from corticosteroid therapy had a 2.5-times
higher nonrelapse mortality and a .6-times lower overall survival rate. The present study demonstrated,
for the ﬁrst time, a higher probability of improvement in grade II to IV acute GVHD with systemic cortico-
steroid therapy in patients after UCB transplantation than in those after BM and PBSC transplantation. A
prospective study is warranted.
 2013 American Society for Blood and Marrow Transplantation. Open access under CC BY-NC-ND license.INTRODUCTION
Despite prophylactic treatment with immunosuppressive
agents, acute graft-versus-host disease (GVHD) remains
a major problem after allogeneic hematopoietic cell trans-
plantation (HCT). Several studies have evaluated a variety ofdgments on page 1189.
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Openagents added to prednisone [1-7], but the use of prednisone
or methylprednisolone alone is recommended as a standard
ﬁrst-line treatment for acute GVHD [8]. The response rate is
approximately 40% to 60%, and patients unresponsive or
resistant to corticosteroid therapy have an increased risk of
mortality related to uncontrolled GVHD [2,9-16]. Some clin-
ical factors are reported to be statistically predictive of
a response to systemic corticosteroid therapy: HLA-
mismatched donor transplantation, unrelated donor trans-
plantation, combination of male recipient and female donor,
early onset of GVHD, higher grade of GVHD, and liver or gut
involvement of GVHD have lower response rates [2,9,10,14]. access under CC BY-NC-ND license.
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studies inwhichmost or all patients underwent bonemarrow
(BM) transplantation. However, stem cell sources for alloge-
neic HCT have changed dramatically with the frequent use of
peripheral blood stem cells (PBSCs) and umbilical cord blood
(UCB), and no study has compared the response rates of
corticosteroid therapy among stem cell sources.
To identify the factors affecting the response to systemic
corticosteroid therapy as a ﬁrst-line treatment for patients
with grade II to IV acute GVHD, a retrospective study was
conducted using the national registry data on 3436 patients
who received ﬁrst allogeneic HCT in Japan with BM
(n ¼ 1955), PBSCs (n ¼ 642), or UCB (n ¼ 839).PATIENTS AND METHODS
Patients
Clinical data for patients who received the ﬁrst allogeneic HCT in Japan,
achieved neutrophil engraftment (>.5  109/L), developed grade II to IV
acute GVHD, and received systemic corticosteroid therapy as a ﬁrst-line
treatment for acute GVHD were extracted from the Transplant Registry
UniﬁedManagement Program system, which is a registry of the outcomes of
Japanese transplantation patients [17]. Patients who relapsed before GVHD
development were excluded, as were patients who received other agents as
initial therapy in addition to systemic corticosteroid therapy. This study was
approved by the Data Management Committee of the Japan Society for
Hematopoietic Cell Transplantation and by the ethical committee of the
Nagoya University School of Medicine.Deﬁnitions
Acute GVHDwas diagnosed and graded according to established criteria
[18]. Persistent nausea with histologic evidence of GVHD but no diarrhea
was included as stage 1 gut GVHD. Responses of acute GVHD to cortico-
steroid therapy were deﬁned as improved if the gradewas improvedwithout
additional systemic treatment. Responses were evaluated without time
limitation, and therefore were considered improved even if the GVHD was
improved later than day 28 of corticosteroid therapy, although response by
day 28 is proposed as the best endpoint to deﬁne need for second-line
treatment [16]. Responses were also considered improved even if acute
GVHD was improved and then a new immunosuppressant was added to
treat chronic GVHD. Responses were deﬁned as stable or progressive if the
gradewas unchanged or worsened after ﬁrst-line corticosteroid therapy or if
second-line systemic treatment for acute GVHD was added regardless of
responsiveness to ﬁrst-line corticosteroid therapy. Thus, all patients who
received second-line treatment for acute GVHD were considered stable or
progressive even if the GVHDwas improved temporarily after corticosteroid
therapy.
Acute myeloid leukemia in the ﬁrst or second remission, acute
lymphoblastic leukemia in the ﬁrst remission, chronic myelogenous
leukemia in the ﬁrst chronic phase, and myelodysplastic syndromes with
refractory anemia or refractory anemia with ringed sideroblasts were
deﬁned as standard-risk malignancies, and other malignant diseases were
deﬁned as high-risk malignancies.
BM transplantation from serological HLA-A, B, and DR 6/6 matched
related donors was deﬁned as MRD-BM, and BM transplantation from
serological HLA-A, B, and DR at least 3/6 matched, but not 6/6 matched
related donors, was deﬁned as MMRD-BM. PBSC transplantation from
serological HLA-A, B, and DR 6/6 matched related donors was deﬁned as
MRD-PB, and PBSC transplantation from serological HLA-A, B, and DR at least
3/6 matched, but not 6/6 matched related donors, was deﬁned asMMRD-PB.
For unrelated BM transplantation, all patientedonor pairs were HLA-typed
to allele level for at least 3 loci (HLA-A, B, and DRB1) during the coordina-
tion process. BM transplantation from HLA-A, B, and DRB1 alleles 6/6
matched unrelated donors was deﬁned asMUD-BM, and BM transplantation
from HLA-A, B, and DRB1 alleles 5/6 or 4/6 matched unrelated donors was
deﬁned as MMUD-BM. UCB transplantation from serological HLA-A, B, and
DR at least 4/6 matched donors was deﬁned as UCB.
Based on the report by the Center for International Blood and Marrow
Transplant Research [19], the conditioning regimens were classiﬁed as
myeloablative if total body irradiation >8 Gy, oral busulfan 9 mg/kg,
intravenous busulfan 7.2 mg/kg, or melphalan >140 mg/m2 was included
in the conditioning regimen, whereas other conditioning regimens were
classiﬁed as nonmyeloablative.
Onset of acute GVHDwas classiﬁed into 3 groups: day28, day29, and
unknown; however, acute GVHD that occurred earlier than day 4, which
might be an error at the time of registration, was classiﬁed into unknown.Endpoints
The primary endpoint of this study was to identify the factors affecting
the response to systemic corticosteroid therapy as a ﬁrst-line treatment for
grade II to IV acute GVHD. The secondary endpoints were to identify factors
associated with nonrelapse mortality (NRM) after corticosteroid therapy
and to evaluate the impact of response to corticosteroid therapy on the
overall survival (OS) rate after corticosteroid therapy.
Statistical Analysis
Univariate and multivariate logistic regression analyses were used to
identify factors associated with the response to corticosteroid therapy. The
probability of NRM after systemic corticosteroid therapy stratiﬁed by
response to corticosteroid therapy was estimated on the basis of cumulative
incidence curves in which relapse was treated as a competing event [20].
The probability of OS after systemic corticosteroid therapy stratiﬁed by
response to corticosteroid therapy was estimated according to the Kaplan-
Meier method [21]. The groups were compared using the log-rank test.
Competing risk regression analysis was used to identify factors associated
with NRM after corticosteroid therapy. The adjusted probability of OS after
corticosteroid therapy was estimated using the Cox proportional hazards
model, with consideration of other signiﬁcant clinical variables in the ﬁnal
multivariate models [22]. P values were 2 sided, and P < .05 was considered
signiﬁcant. The following covariates were considered for the multivariate
models: patient age, patient sex, sex mismatch between patient and donor,
disease, stem cell source, cytomegalovirus serostatus, preconditioning,
GVHD prophylaxis, in vivo T cell depletion, year of transplantation, onset of
acute GVHD, grade of acute GVHD, organ involvement of acute GVHD, and
response to systemic corticosteroid therapy (improved or stable/progres-
sive). The data were analyzed by STATA version 12 statistical software
(StataCorp, TX).
RESULTS
Patient, Transplantation, and GVHD Characteristics
A total of 3436 patients met the inclusion criteria. Patient
and transplantation characteristics are shown in Table 1.
Patient age at transplantation ranged from 0 to 82 years
(median, 40 years); the number of patients age<18, 18 to 49,
and 50 years was 672, 1626, and 1138, respectively. Stem
cell sources were BM (n ¼ 1955), PBSC (n ¼ 642), and UCB
(n ¼ 839). All UCB transplantation was performed with
a single unit. In vivo T cell depletion was performed in 168
(5%) patients by either antithymocyte globulin or anti-
lymphocyte globulin. No other drugs, such as alemtuzumab,
were used for in vivo T cell depletion, nor was ex vivo T cell
depletion used in any patients. The year of transplantation
ranged from 1984 to 2009; the majority of cases (94%) were
performed in 2000 or later.
Characteristics of acute GVHD cases are shown in Table 2.
The numbers of patients who developed acute GVHD at day
28 and day 29 were 2344 and 994, respectively. Of 3436
patients who received systemic corticosteroid therapy as the
ﬁrst-line treatment for grade II to IV acute GVHD, 2190
(63.7%) showed improvement of acute GVHD.
Factors Associated with Improvement of GVHD by
Corticosteroid Therapy
MUD-BM, HLA-mismatched stem cell source other than
UCB (MMRD-BM, MMRD-PB, and MMUD-BM), more severe
acute GVHD, andmultiple organ involvement of acute GVHD,
including gut, were signiﬁcantly associated with a lower
probability of improvement by corticosteroid therapy
(Table 3). On the other hand, adult patient (ages 18 to
49 years) and UCBwere signiﬁcantly associatedwith a higher
probability of improvement by corticosteroid therapy
(Table 3). Although some factors, such as disease, cytomeg-
alovirus serostatus, and preconditioning, were signiﬁcant for
corticosteroid response in univariate analysis, they were not
signiﬁcant in multivariate analysis. Additional analysis in
which onset of acute GVHD was modeled as a continuous
variable could not detect a signiﬁcant association between
Table 1
Patient and Transplantation Characteristics (N ¼ 3436)
Characteristic Total (N ¼ 3246) MRD-BM/PB (n ¼ 926) MUD-BM þ mm* (n ¼ 1671) UCB (n ¼ 839)
Patient age at transplantation
<18 yr 672 (20) 99 (11) 310 (19) 263 (31)
18 to 49 yr 1626 (47) 520 (56) 836 (50) 270 (32)
50 yr 1138 (33) 307 (33) 525 (31) 306 (37)
Patient sex
Female 1393 (41) 380 (41) 668 (40) 345 (41)
Male 2043 (59) 546 (59) 1003 (60) 494 (59)
Sex mismatch between patient and donor
Female donor to male patient 815 (24) 251 (27) 348 (21) 216 (26)
Other combinations 2525 (73) 662 (72) 1321 (79) 542 (64)
Unknown 96 (3) 13 (1) 2 (0) 81 (10)
Disease
Standard-risk malignancies 1320 (38) 372 (40) 686 (41) 262 (31)
High-risk malignancies 1926 (57) 509 (55) 900 (54) 517 (62)
Nonmalignancies 154 (4) 40 (4) 80 (5) 34 (4)
Unknown 36 (1) 5 (1) 5 (0) 26 (3)
Stem cell source
MRD-BM 445 (13) 445 (48) 0 (0) 0 (0)
MRD-PB 481 (14) 481 (52) 0 (0) 0 (0)
MUD-BM 783 (23) 0 (0) 783 (47) 0 (0)
UCB 839 (24) 0 (0) 0 (0) 839 (100)
MMRD-BM 155 (4) 0 (0) 155 (9) 0 (0)
MMRD-PB 161 (5) 0 (0) 161 (10) 0 (0)
MMUD-BM 572 (17) 0 (0) 572 (34) 0 (0)
Cytomegalovirus serostatus
Negative donor to negative patient 322 (9) 53 (6) 112 (7) 159 (19)
Positive donor to negative patient 215 (6) 64 (7) 149 (9) 0 (0)
Negative donor to positive patient 899 (26) 107 (12) 290 (17) 509 (61)
Positive donor to positive patient 1541 (46) 574 (61) 960 (57) 0 (0)
Unknown 459 (13) 128 (14) 160 (10) 171 (20)
Preconditioning
Myeloablative 2094 (61) 578 (62) 1030 (62) 486 (58)
Nonmyeloablative 1307 (38) 323 (35) 636 (38) 348 (41)
Unknown 35 (1) 25 (3) 5 (0) 5 (1)
GVHD prophylaxis
Cyclosporine Aebased 1676 (49) 800 (87) 417 (25) 459 (55)
Tacrolimus-based 1691 (49) 103 (11) 1227 (73) 361 (43)
Others 56 (2) 20 (2) 26 (2) 10 (1)
Unknown 13 (0) 3 (0) 1 (0) 9 (1)
In vivo T cell depletion
No 3251 (95) 876 (94) 1556 (93) 819 (98)
Yes 168 (5) 34 (4) 115 (7) 19 (2)
Unknown 17 (0) 16 (2) 0 (0) 1 (0)
Year of transplantation
1984 to 1999 200 (6) 103 (11) 63 (4) 34 (4)
2000 to 2004 721 (21) 182 (20) 221 (13) 318 (38)
2005 to 2009 2515 (73) 641 (69) 1387 (83) 487 (58)
MRD-BM indicates HLA-matched related donor bone marrow; MRD-PB, HLA-matched related donor peripheral blood stem cells; MUD-BM, HLA-matched
unrelated donor bone marrow; UCB, umbilical cord blood; MMRD-BM, HLA-mismatched related donor bone marrow; MMRD-PB, HLA-mismatched related
donor peripheral blood stem cells; MMUD-BM, HLA-mismatched unrelated donor bone marrow; GVHD, graft-versus-host disease.
Data presented are n (%).
* mm indicates MMRD-BM, MMRD-PB, and MMUD-BM.
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Response rates to corticosteroid therapy in each stem cell
source are summarized in Table 4.
Impact of the Response to Corticosteroid Therapy on NRM
The cumulative incidence rates of NRM after systemic
corticosteroid therapy for grade II to IV acute GVHD are
shown in Figure 1. Patients who did not achieve improve-
ment of acute GVHD by corticosteroid therapy had a signiﬁ-
cantly higher NRM compared with those who achieved
improvement (P < .0001).
To identify factorsassociatedwithNRMaftercorticosteroid
therapy for grade II to IV acute GVHD, competing risk regres-
sion analysis was performed. The patients with a stable or
progressive response to corticosteroid therapy were approx-
imately 2.5 times more likely to have NRM than patients with
an improved response to corticosteroid therapy (Table 5).Other factors associated with signiﬁcantly worse NRM
included older patient age (18 to 49 years and 50 years),
higher grades of acute GVHD (grades III and IV), and liver or
multiple organ involvement including liver of acute GVHD
(Table 5). Although some factors such as patient sex, disease,
and preconditioning were signiﬁcant for NRM in univariate
analysis, they were not signiﬁcant in multivariate analysis.
Additional analysis in which onset of acute GVHD was
modeledasa continuousvariablecouldnotdetecta signiﬁcant
association between onset of acute GVHD and NRM.
Impact of the Response to Corticosteroid Therapy on the
OS Rate
The Kaplan-Meier estimates of OS rates after systemic
corticosteroid therapy for grade II to IV acute GVHD are
shown in Figure 2. Patients who did not achieve improve-
ment of acute GVHD by corticosteroid therapy had
Table 2
Acute GVHD Characteristics
Characteristic Total (N ¼ 3436) MRD-BM/PB (n ¼ 926) MUD-BM þ mm* (n ¼ 1671) UCB (n ¼ 839)
Onset of acute GVHD
Day 28 2344 (68) 560 (60) 1221 (73) 563 (67)
Day 29 994 (29) 351 (38) 434 (26) 209 (25)
Unknown 98 (3) 15 (2) 16 (1) 67 (8)
Grade of acute GVHD
II 2049 (59) 584 (63) 973 (58) 492 (58)
III 1015 (30) 259 (28) 482 (29) 274 (33)
IV 372 (11) 83 (9) 216 (13) 73 (9)
Organ involvement
Skin only 1110 (32) 288 (31) 579 (34) 243 (29)
Gut only 310 (9) 125 (13) 129 (8) 55 (7)
Liver only 35 (1) 8 (1) 16 (1) 11 (1)
Skin and gut, no liver 1178 (34) 316 (34) 576 (34) 286 (34)
Skin and liver, no gut 177 (5) 56 (6) 72 (4) 49 (6)
Gut and liver, no skin 87 (3) 26 (3) 42 (3) 19 (2)
Skin, gut, and liver 487 (14) 107 (12) 256 (16) 124 (15)
Unknown 52 (2) 0 (0) 1 (0) 51 (6)
GVHD indicates graft-versus-host disease; MRD-BM/PB, HLA-matched related donor bone marrow and HLA-matched related donor peripheral blood stem cells;
MUD-BM, HLA-matched unrelated donor bone marrow; UCB, umbilical cord blood.
Data are presented as n (%).
* mm indicates HLA-mismatched related donor bone marrow, HLA-mismatched related donor peripheral blood stem cells and HLA-mismatched unrelated
donor bone marrow.
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improvement (P < .0001).
To evaluate the impact of the response to corticosteroid
therapy on the OS rate, the Cox proportional hazards model
was usedwith all of the clinical features listed in Tables 1 and
2. On univariate analysis, the OS rate was signiﬁcantly lowerTable 3
Factors Associated with Improvement of GVHD by Corticosteroid Therapy
Factor (n) Univariate Analysis Relative Risk* (95% CI)
Patient age
<18 yr (672) 1
18 to 49 yr (1626) 1.33 (1.10 to 1.60)
50 yr (1138) 1.06 (.88 to 1.30)
Stem cell source
MRD-BM (445) 1
MRD-PB (481) .66 (.50 to .87)
MUD-BM (783) .53 (.41 to .68)
UCB (839) .97 (.75 to 1.26)
MMRD-BM (155) .26 (.18 to .39)
MMRD-PB (161) .34 (.23 to .49)
MMUD-BM (572) .47 (.36 to .61)
GVHD prophylaxis
Cyclosporine A-based (1676) 1
Tacrolimus-based (1691) .80 (.69 to .92)
Other (56) .38 (.22 to .64)
In vivo T cell depletion
No (3251) 1
Yes (168) 1.47 (1.08 to 2.01)
Onset of acute GVHD
Day 28 (2344) 1
Day 29 (994) 1.20 (1.03 to 1.40)
Grade of acute GVHD
II (2049) 1
III (1015) .34 (.29 to .39)
IV (372) .04 (.03 to .06)
Organ involvement
Skin only (1110) 1
Gut only (310) .69 (.52 to .92)
Liver only (35) .22 (.11 to .43)
Skin and gut, no liver (1178) .55 (.45 to .66)
Skin and liver, no gut (177) .39 (.28 to .54)
Gut and liver, no skin (87) .17 (.11 to .26)
Skin, gut, and liver (487) .13 (.10 to .17)
GVHD indicates graft-versus-host disease; MRD-BM, HLA-matched related donor
cells; MUD-BM, HLA-matched unrelated donor bone marrow; UCB, umbilical cord b
HLA-mismatched related donor peripheral blood stem cells; MMUD-BM, HLA-mis
* Values >1.0 indicate higher probability of improvement; values <1.0 indicatein patients with a stable or progressive response to cortico-
steroid therapy than in patients with an improved response
(hazard ratio, 2.18; 95% conﬁdence interval, 1.97 to 2.40).
After adjustment by patient age, disease, preconditioning,
grade of acute GVHD, and organ involvement of acute GVHD,
which were signiﬁcant on univariate analysis, the OS rateP Value Multivariate Analysis Relative Risk* (95% CI) P Value
1
.003 1.48 (1.18 to 1.85) <.002
.509 1.11 (.88 to 1.40) .385
1
.004 .81 (.59 to 1.12) .201
<.001 .57 (.43 to .76) <.001
.839 1.36 (1.01 to 1.83) .042
<.001 .37 (.24 to .57) <.001
<.001 .41 (.27 to .63) <.001
<.001 .57 (.42 to .77) <.001
1
.002 1.02 (.82 to 1.26) .851
<.001 .61 (.31 to 1.22) .164
1
.015 1.06 (.68 to 1.65) .787
1
.023 1.10 (.91 to 1.34) .336
1
<.001 .45 (.37 to .55) <.001
<.001 .07 (.05 to .10) <.001
1
.011 .91 (.66 to 1.24) .541
<.001 .56 (.25 to 1.25) .157
<.001 .77 (.62 to .96) .021
<.001 .78 (.53 to 1.15) .214
<.001 .36 (.21 to .59) <.001
<.001 .38 (.28 to .51) <.001
bone marrow; MRD-PB, HLA-matched related donor peripheral blood stem
lood; MMRD-BM, HLA-mismatched related donor bone marrow; MMRD-PB,
matched unrelated donor bone marrow; CI, conﬁdence interval.
lower probability.
Table 4
Response to Corticosteroid Therapy in Each Stem Cell Source
Stem Cell Source No. of Cases Patients with Improved
Response, n (%)
MRD-BM 445 328 (73.7)
MRD-PB 481 312 (64.9)
MUD-BM 783 468 (59.8)
UCB 839 614 (73.2)
MMRD-BM 155 66 (42.9)
MMRD-PB 161 78 (48.4)
MMUD-BM 572 324 (56.6)
Total 3436 2190 (63.7)
MRD-BM indicates HLA-matched related donor bone marrow; MRD-PB,
HLA-matched related donor peripheral blood stem cells; MUD-BM, HLA-
matched unrelated donor bone marrow; UCB, umbilical cord blood;
MMRD-BM, HLA-mismatched related donor bone marrow; MMRD-PB,
HLA-mismatched related donor peripheral blood stem cells; MMUD-BM,
HLA-mismatched unrelated donor bone marrow.
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progressive response to corticosteroid therapy than in
patients with an improved response (hazard ratio, 1.66; 95%
conﬁdence interval, 1.49 to 1.85).DISCUSSION
The present nationwide study revealed that the response
rate of grade II to IV acute GVHD to systemic corticosteroid
therapy in Japanese patients was approximately 64%, which
is comparable to that in Caucasian patients. In a retrospective
analysis of 456 patients who were treated with methyl-
prednisolone 2 mg/kg/day for grade II to IV acute GVHD after
allogeneic BM transplantation at the Fred Hutchinson Cancer
Research Center, 59% of the patients experienced a complete,
partial, or mixed response [10]. In another retrospective
analysis of 864 patients who were treated with prednisone
60 mg/m2/day for grade II to IV acute GVHD after BM, PBSC,
or UCB transplantation at the University of Minnesota, 65% of
the patients experienced a complete, very good partial, or
partial response [16].
The factors associated with poor response to corticoste-
roid therapy were MUD-BM, HLA-mismatched stem cellFigure 1. Nonrelapse mortality (NRM) after systemic corticosteroid therapy
for patients with grade II to IV acute GVHD. Cumulative incidence rates of NRM
after systemic corticosteroid therapy in patients (n ¼ 1992) with an improved
response to corticosteroid therapy (dashed line, 22.2% [95% conﬁdence
interval, 20.1% to 24.4%] at 2 years, 30.1% [27.1% to 33.0%] at 5 years, 33.5%
[29.4% to 37.6%] at 10 years, and 41.8% [26.2% to 56.7%] at 15 years) and
patients (n ¼ 1119) with a stable or progressive response to corticosteroid
therapy (solid line, 56.3% [53.1% to 59.5%] at 2 years, 61.4% [57.7% to 64.9%] at
5 years, 63.4% [59.2% to 67.3%] at 10 years, and 63.4% [59.2% to 67.3%] at
15 years) are shown (P < .0001).sources other than UCB (MMRD-BM, MMRD-PB, and
MMUD-BM), more severe acute GVHD, and multiple organ
involvement including gut of acute GVHD (Table 3). The
previous studies also found these features as risk factors for
an increased treatment failure rate [9,10], suggesting that
these subgroups may be targets for alternate ﬁrst-line
immunosuppressive therapies.
On the other hand, UCB was identiﬁed as a factor associated
with a higher response to ﬁrst-line corticosteroid therapy in
the present study (Table 3). Although several studies
havedemonstratedasigniﬁcantly lower incidenceofacuteGVHD
in UCB transplantation than in unrelated BM transplantation
[23-29], no study has compared the response to treatment of
acuteGVHDbetween them. Thepresent studydemonstrated, for
the ﬁrst time, a higher response of grade II to IV acute GVHD to
systemic corticosteroid therapy in patients after UCB trans-
plantation than in those after BM or PBSC transplantation.
Nevertheless, UCB transplantation had no impact on NRM
after corticosteroid therapy in the multivariate analysis and,
in fact, had higher NRM thanMRD-BM transplantation in the
univariate analysis (Table 5). Thus, even though there was
a higher response of acute GVHD to systemic corticosteroid
therapy in patients after UCB transplantation, careful
management is required for patients who suffer from grade II
to IV acute GVHD after UCB transplantation, as well as those
after transplantation with other stem cell sources.
Unexpectedly, adult patient (ages 18 to 49 years) was
predictive of a good response to systemic corticosteroid
therapy compared with child patient (age <18 years). Addi-
tional analysis was performed, and it was found that patients
with grade II acute GVHD accounted for 61.4% of adult patient
group, whereas 56.1% of child patient group (Fisher exact
test, P ¼ .019). This difference might affect the above result
because severity of acute GVHD was the most signiﬁcant
factor associated with response to corticosteroid therapy
(Table 3). Nonetheless, adult patients were likely to have
higher NRM than child patients (Table 5). Our data indicate
that although adult patients may be more responsive to
corticosteroid therapy for acute GVHD, they have a higher risk
of transplant-related toxicity than childrenwith acute GVHD.
Despite the fact that multivariate analysis showed
asigniﬁcantlyhigher response rate to corticosteroid therapy in
UCB transplantation thanMRD-BMtransplantation, the actual
percentage was similar between UCB (73.2%) and MRD-BM
(73.7%) transplantations (Table 4). Additional analysis found
that patients in the age group 18 to 49 years (predictive factor
of good response) accounted for only 32.2% of UCB trans-
plantation, but constituted 58.4% of the MRD-BM population
(Fisher exact test, P < .001) and that patients with grade II
acuteGVHD (predictive factor of good response) accounted for
only 58.6% ofUCB transplantation, but constituted 70.1%of the
MRD-BM population (Fisher exact test, P < .001). These data
suggested that the UCB population included fewer patients
having predictive factors of good response to corticosteroid
therapy compared with the MRD-BM population. This could
explain why the actual percentage of patients with an
improved response in UCB transplantation was almost the
sameas thepercentage of patientswith an improved response
in MRD-BM transplantation.
Interestingly, multiorgan involvement that includes the
gut was less likely to respond to ﬁrst-line therapy with
corticosteroids (Table 3); however, patients with liver
involvement are more likely to have higher NRM (Table 5).
Further study is required to elucidate the mechanisms of the
difference in the effect of gut and liver GVHD on
Table 5
Factors Associated with Nonrelapse Mortality after Corticosteroid Therapy
Factor (n) Univariate Analysis
Hazard Ratio* (95% CI)
P Value Multivariate Analysis
Hazard Ratio* (95% CI)
P Value
Patient age
<18 yr (554) 1 1
18 to 49 yr (1503) 1.50 (1.21 to 1.85) <.001 1.72 (1.38 to 2.14) <.001
50 yr (1054) 2.74 (2.22 to 3.38) <.001 3.34 (2.67 to 4.17) <.001
Stem cell source
MRD-BM (402) 1 1
MRD-PB (447) 1.43 (1.11 to 1.83) .005 .88 (.68 to 1.15) .344
MUD-BM (726) 1.40 (1.11 to 1.77) .004 1.02 (.80 to 1.30) .866
UCB (720) 1.35 (1.06 to 1.71) .014 1.15 (.90 to 1.48) .265
MMRD-BM (141) 1.63 (1.16 to 2.28) .005 1.15 (.82 to 1.62) .415
MMRD-PB (153) 1.74 (1.26 to 2.39) .001 .97 (.69 to 1.37) .882
MMUD-BM (522) 1.79 (1.41 to 2.27) <.001 1.25 (.97 to 1.60) .082
GVHD prophylaxis
Cyclosporine A-based (1528) 1
Tacrolimus-based (1520) 1.06 (.94 to 1.21) .332
Other (50) 1.28 (.81 to 2.04) .296
In vivo T cell depletion
No (3004) 1
Yes (91) .98 (.66 to 1.44) .919
Onset of acute GVHD
Day 28 (2212) 1
Day 29 (899) 1.05 (.92 to 1.20) .476
Grade of acute GVHD
II (1864) 1 1
III (917) 2.21 (1.92 to 2.56) <.001 1.56 (1.31 to 1.86) <.001
IV (330) 7.93 (6.67 to 9.43) <.001 3.53 (2.84 to 4.38) <.001
Organ involvement
Skin only (1010) 1 1
Gut only (266) 1.11 (.84 to 1.47) .448 .80 (.59 to 1.08) .139
Liver only (28) 4.11 (2.20 to 7.69) <.001 2.22 (1.19 to 4.16) .013
Skin and gut, no liver (1083) 1.27 (1.06 to 1.51) .008 .97 (.79 to 1.18) .753
Skin and liver, no gut (160) 2.42 (1.83 to 3.21) <.001 1.54 (1.13 to 2.08) .006
Gut and liver, no skin (75) 3.64 (2.57 to 5.16) <.001 1.88 (1.29 to 2.73) .001
Skin, gut, and liver (448) 4.82 (4.03 to 5.77) <.001 2.07 (1.64 to 2.62) <.001
Response to systemic corticosteroid
therapy
Improved (1992) 1 1
Stable/progressive (1119) 3.63 (3.20 to 4.12) <.001 2.45 (2.14 to 2.82) <.001
MRD-BM indicates HLA-matched related donor bone marrow; MRD-PB, HLA-matched related donor peripheral blood stem cells; MUD-BM, HLA-matched
unrelated donor bone marrow; UCB, umbilical cord blood; MMRD-BM, HLA-mismatched related donor bone marrow; MMRD-PB, HLA-mismatched related
donor peripheral blood stem cells; MMUD-BM, HLA-mismatched unrelated donor bone marrow; GVHD, graft-versus-host disease; CI, conﬁdence interval.
* Values >1.0 indicate higher probability of non relapse mortality; values <1.0 indicate lower probability.
M. Murata et al. / Biol Blood Marrow Transplant 19 (2013) 1183e11891188transplantation outcome. Nevertheless, lack of response to
initial therapy is an important risk factor in predicting high
NRM in patients with grade II to IV acute GVHD (Table 5).Figure 2. Overall survival (OS) for patientswith grade II to IV acuteGVHD.OS for
patients (n ¼ 2190) with an improved response (dashed line; 61.3% [95% conﬁ-
dence interval, 59.0% to 63.5%] at 2 years, 51.9% [49.2% to 54.5%] at 5 years, 47.8%
[44.0% to 51.5%] at 10 years, and 43.8% [35.5% to 51.8%] at 15 years) and OS for
patients (n¼1246)with a stable or progressive response (solid line; 37.4% [34.6%
to 40.3%] at 2 years, 32.5% [29.5% to 35.6%] at 5 years, 30.6% [27.3% to 34.1%] at
10 years, and 30.6% [27.3% to 34.1%] at 15 years) are shown (P < .0001).The patients who did not achieve improvement of acute
GVHD by corticosteroid therapy had approximately 2.5-times
higher NRM and approximately .6-times lower OS rates. It is
well known that the incidence of acute GVHD in Japanese
patients is lower than that in Caucasian patients [30,31].
However, the present data clearly demonstrate that, if the
systemic corticosteroid therapy is ineffective, even Japanese
patients cannot achieve a satisfactory survival rate. Another
important message of this study is that the establishment of
second-line treatment for corticosteroid-refractory acute
GVHD is required for not only Caucasian, but also for Japanese
patients.
This study had several limitations. First, the sort and dose
of corticosteroids are not collected in the Japan Society for
Hematopoietic Cell Transplantationdatabase. Inpatientswith
grade II to IV acute GVHD, initial treatment with prednisone-
equivalent steroid doses higher than 2.5 mg/kg has not been
shown to provide better outcomes [32], although in patients
with grade II acute GVHD, lower-dose initial treatment at
1.0 mg/kg has not been shown to provide worse outcomes
[33]. The intensityof corticosteroid therapymaydiffer byeach
transplantation team or each patient, as shown by a survey in
Europe [34], and this information may give us additional
ﬁndings. Second, criteria for improvement, or for stable or
progressive acute GVHD, had been previously deﬁned in the
M. Murata et al. / Biol Blood Marrow Transplant 19 (2013) 1183e1189 1189database, which did not allow for analysis by outcomes such
as complete, partial, or mixed response, as has been per-
formed in previous studies [10,16]. Third, the time of the
evaluation of GVHD is not deﬁned in the database. Thus, the
responsewas evaluated using anonﬁxed timepoint, although
GVHD sometimes shows a waxing and waning course. This
also prevented us fromanalyzing the speed of the response to
therapy. A recent study has reported that the day-28 response
to corticosteroid therapy can predict the outcomes for
patients with acute GVHD [16]. Fourth, this study was
a retrospective analysis, which is challenging given the
heterogeneous background.Multivariate analysiswas used to
attempt to reduce statistical bias, but a prospective study is
required to validate the present ﬁndings.
The results of this large retrospective study showed
a higher response of acute GVHD to systemic corticosteroid
therapy in patients after UCB transplantation than for
patients after BM and PBSC transplantation, and conﬁrmed
the factors previously reported. These results should be
considered in the design of future clinical trials of acute
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